Covestor’s Ocular Therapeutix OCUL Stock Holding History

Covestor’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$0	Buy	47 +33	+236%	+$299	﹤0.01%	2735
2026 Q1	$0	Buy	14 +1	+8%	+$10	﹤0.01%	2625
2025 Q4	$0	Sell	13 -1	-7%	-$12	﹤0.01%	2601
2025 Q3	$0	Hold	14	–	–	﹤0.01%	2614
2025 Q2	$0	Sell	14 -1	-7%	-$8	﹤0.01%	2588
2025 Q1	$0	Hold	15	–	–	﹤0.01%	2579
2024 Q4	$0	Buy	15 +1	+7%	+$10	﹤0.01%	2586
2024 Q3	$0	Sell	14 -10	-42%	-$82	﹤0.01%	2586
2024 Q2	$0	Buy	+24	New	+$148	﹤0.01%	2598
2024 Q1	–	Sell	-7,525	Closed	-$34K	–	2587
2023 Q4	$34K	Sell	7,525 -29,879	-80%	-$88.4K	0.02%	999
2023 Q3	$117K	Buy	37,404 +1,729	+5%	+$7.08K	0.09%	333
2023 Q2	$184K	Sell	35,675 -24,333	-41%	-$145K	0.14%	145
2023 Q1	$316K	Buy	60,008 +43,349	+260%	+$206K	0.28%	39
2022 Q4	$47K	Buy	+16,659	New	+$55.2K	0.04%	756

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Covestor's OCUL Position: Q2 2026 in Review

Covestor increased its Ocular Therapeutix (OCUL) stake by 236% in Q2 2026, buying an estimated $299 and bringing the position to 47 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2735.

Covestor first reported a position in OCUL in Q4 2022 and has held it in 14 quarters since. The position peaked at $316K in Q1 2023. 262 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Covestor held 47 shares of Ocular Therapeutix worth $0 as of Q2 2026.
Covestor bought 33 Ocular Therapeutix shares in Q2 2026, an estimated $299.
Ocular Therapeutix made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2735 holding.
Covestor first reported a position in Ocular Therapeutix in Q4 2022 and has held it in 14 quarters since.
Covestor's Ocular Therapeutix position peaked at $316K in Q1 2023.
262 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.